P 1037

Drug Profile

P 1037

Alternative Names: GS-5737; P-1037; VX 371

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Parion Sciences
  • Developer Parion Sciences; Vertex Pharmaceuticals
  • Class Antibronchitics
  • Mechanism of Action Epithelial sodium channel-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis; Primary ciliary dyskinesia

Most Recent Events

  • 25 Oct 2017 Safety and efficacy data from a phase IIa trial in Cystic fibrosis released by Vertex Pharmaceuticals
  • 01 Sep 2017 Vertex Pharmaceuticals completes a phase II trial in Cystic fibrosis (In adolescents, In adults) in USA, United Kingdom, Czech Republic, France and Ireland (Inhalation) (NCT02709109)
  • 23 Feb 2017 Vertex Pharmaceuticals has patent protection for P 1037 in USA and outside USA (Vertex Pharmaceuticals form 10-K, filed in February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top